Literature DB >> 2072460

Respiratory syncytial virus infection in C57BL/6 mice: clearance of virus from the lungs with virus-specific cytotoxic T cells.

J L Muñoz1, C A McCarthy, M E Clark, C B Hall.   

Abstract

We describe respiratory syncytial virus (RSV)-specific cytotoxic T-cell (CTL) lines and clones developed from the spleens of C57BL/6 and BALB/c mice. Line 7 and clones derived from it were H-2Kb restricted, whereas line 12 had both Kb and Db components. Both lines, and all the clones except one, could lyse targets infected with either strain A or strain B RSV. Line 7 or 7-11E1 cells (8 x 10(6) to 10 x 10(6) given intravenously cleared RSV from the lungs of infected mice. There was no morbidity or mortality in any of the infected mice whether or not they received T cells. The C57BL/6 mouse is a useful model system in which to study the role of the CTL response in protective immunity to RSV. CTL lines and clones can mediate clearance of RSV from the lungs of normal mice without producing any associated morbidity.

Entities:  

Mesh:

Year:  1991        PMID: 2072460      PMCID: PMC248892          DOI: 10.1128/JVI.65.8.4494-4497.1991

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens.

Authors:  P J Bjorkman; M A Saper; B Samraoui; W S Bennett; J L Strominger; D C Wiley
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

2.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

3.  Recognition of Db and Kb gene products by influenza-specific cytotoxic T cells.

Authors:  A R Townsend; P M Taylor; A L Mellor; B A Askonas
Journal:  Immunogenetics       Date:  1983       Impact factor: 2.846

4.  Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model.

Authors:  V G Hemming; G A Prince; R L Horswood; W J London; B R Murphy; E E Walsh; G W Fischer; L E Weisman; P A Baron; R M Chanock
Journal:  J Infect Dis       Date:  1985-11       Impact factor: 5.226

5.  The development of Balb/c cells persistently infected with respiratory syncytial virus: presence of ribonucleoprotein on the cell surface.

Authors:  B F Fernie; E C Ford; J L Gerin
Journal:  Proc Soc Exp Biol Med       Date:  1981-05

6.  A simplified method for the production of murine T-cell growth factor free of lectin.

Authors:  P J Spiess; S A Rosenberg
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

7.  Respiratory syncytial virus infection in mice.

Authors:  G Taylor; E J Stott; M Hughes; A P Collins
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

8.  Cytotoxic T-cell response to respiratory syncytial virus in mice.

Authors:  C R Bangham; M J Cannon; D T Karzon; B A Askonas
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

9.  Development of a serum-free medium which supports the long-term growth of human and nonhuman primate lymphoid cells.

Authors:  R L Brown; R L Griffith; R H Neubauer; H Rabin
Journal:  J Cell Physiol       Date:  1983-05       Impact factor: 6.384

10.  Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus.

Authors:  M J Cannon; P J Openshaw; B A Askonas
Journal:  J Exp Med       Date:  1988-09-01       Impact factor: 14.307

View more
  30 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adults.

Authors:  Adriana Weinberg; Stacie L Lambert; Jennifer Canniff; Li Yu; Nancy Lang; Mark T Esser; Judith Falloon; Myron J Levin
Journal:  Hum Vaccin Immunother       Date:  2019-06-03       Impact factor: 3.452

3.  Alternative mechanisms of respiratory syncytial virus clearance in perforin knockout mice lead to enhanced disease.

Authors:  S Aung; J A Rutigliano; B S Graham
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 4.  Immunopathological mechanisms in respiratory syncytial virus disease.

Authors:  P J Openshaw
Journal:  Springer Semin Immunopathol       Date:  1995

5.  Amino acid variation within the fusion protein of respiratory syncytial virus subtype A and B strains during annual epidemics in South Africa.

Authors:  Elizabeth Agenbach; Caroline T Tiemessen; Marietjie Venter
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

6.  Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus.

Authors:  Y W Tang; B S Graham
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

7.  Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus.

Authors:  L M Haynes; D D Moore; E A Kurt-Jones; R W Finberg; L J Anderson; R A Tripp
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Disruption of the airway epithelial barrier in a murine model of respiratory syncytial virus infection.

Authors:  Carrie C Smallcombe; Debra T Linfield; Terri J Harford; Vladimir Bokun; Andrei I Ivanov; Giovanni Piedimonte; Fariba Rezaee
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-11-29       Impact factor: 5.464

Review 9.  Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

Authors:  V G Hemming; G A Prince; J R Groothuis; G R Siber
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

10.  The induction of respiratory syncytial virus-specific cytotoxic T-cell responses following immunization with a synthetic peptide containing a fusion peptide linked to a cytotoxic T lymphocyte epitope.

Authors:  S C Hsu; D M Shaw; M W Steward
Journal:  Immunology       Date:  1995-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.